The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-27 and is reviewed periodically as new material appears.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
=== Caffeine content of decaffeinated coffee === To ensure product quality, manufacturers are required to test the newly decaffeinated coffee beans to make sure that caffeine concentration is relatively low. A caffeine content reduction of at least 97% is required under United States standards. There is less than 0.1% caffeine in decaffeinated coffee and less than 0.3% in decaffeinated instant coffee in Canada. Many coffee companies use high-performance liquid chromatography (HPLC) to measure how much caffeine remains in the coffee beans. However, since HPLC can be quite costly, some coffee companies are beginning to use other methods such as near-infrared (NIR) spectroscopy. Although HPLC is highly accurate, NIR spectroscopy is much faster, cheaper and overall easier to use. Lastly, another method typically used to measure the remaining caffeine includes ultraviolet–visible spectroscopy: useful for decaffeination processes that include supercritical CO2, as CO2 does not absorb in the UV-Vis range. A controlled study in 2006 at Florida State University consisting of ten samples of prepared decaffeinated coffee from coffee shops showed that some caffeine remained. Fourteen to twenty cups of such decaffeinated coffee would contain as much caffeine as one cup of regular coffee. The 473 ml (16 ounce) cups of coffee samples contained caffeine in the range of 8.6 mg to 13.9 mg. In another study of popular brands of decaf coffees, the caffeine content varied from 3 mg to 32 mg.
== Signs and symptoms == LNS is characterized by three major hallmarks: neurologic dysfunction, cognitive and behavioral disturbances including self-mutilation, and uric acid overproduction (hyperuricemia). Damage to the basal ganglia causes affected individuals to adopt a characteristic fencing stance due to the nature of the lesion. Some may also have macrocytic anemia due to the faulty DNA synthesis, most likely due to deficient purine synthesis that leads to a lag of cell division with respect to increases in cell mass. Virtually all patients are male; males experience delayed growth and puberty, and most develop shrunken testicles or testicular atrophy. Female carriers are at an increased risk for gouty arthritis but are usually otherwise unaffected.
=== Elements regarding the consideration of gender in medicine === Efforts to incorporate gender into medical research began in the late 1980s, primarily in the United States. In 1995, the World Health Organization (WHO) established the Department of Gender and Women's Health. Several European countries followed in the early 2000s by creating research bodies focused on gender in medicine. In France, the "Gender and Health Research" group was created at Inserm in 2013. Public institutions such as French National Public Health Agency and the Haute Autorité de Santé (HAS) have since addressed gender disparities in research and treatment.
Chicks and adult birds' picking at each other until blood shows and then destroying one another by further picking is a source of great loss in many flocks, especially when kept in confinement ... The recommendation of the Ohio Experiment Station of cutting back the tip of the upper beak has been found to be effective until the beak grows out again.
In Australia, PLEs are shown on Main Event. In the United Kingdom and Ireland, all PLEs were shown on Sky Sports Box Office until 2019, when BT Sport took over rights to WWE content. In India and South Asia, a single broadcaster (currently Sony Ten) generally holds the rights to all WWE programming, with PLEs broadcast for no additional charge. Currently, WWE's PLEs for the Raw and SmackDown brands are generally held on Saturdays and are typically 3 to 4 hours in length, with some events running longer or shorter. NXT's PLEs have also mostly shifted to Saturdays and last between 2 to 3 hours. Prior to 2022, all PLEs were generally held on Sundays. The change was attributed to WWE president Nick Khan who felt that "big sports events were better on Saturday nights". WWE also airs a pre-show before most events which includes interviews, match previews, and a panel of experts analyzing the upcoming line-up. They were originally simply called Pre-Show, but beginning with Payback 2013, they were rebranded as Kickoff (although WrestleMania XXX in 2014 used the Pre-Show branding) before being rebranded again to WWE Countdown to [event] beginning with NXT Stand & Deliver in 2024. The pre-shows also used to host some matches but these were phased out in early 2022, although some pre-shows still occasionally have matches. WWE also airs a post-show media press conference following some events, including NXT events. Previously, they would air a post-show for some events, known as Fallout. Each Fallout included interviews and a panel of experts analyzing the event.
Sources: en.wikipedia.org
=== 250Cm === Curium-250 is the isotope with the lowest atomic number that primarily decays by spontaneous fission, a process that releases many times more energy than alpha decay. Compared to plutonium-238, curium-250 has about a quarter of the power density, but 95 times the half-life (~8300 years vs. ~87 years). As it is a neutron emitter (weaker than californium-252 but not negligible) some applications require a further shielding against neutron radiation. As lead, which is an excellent shielding material against gamma rays and beta ray induced Bremsstrahlung, is not a good neutron shield (instead reflecting most of them), a different shielding material would have to be added in applications where neutrons are a concern.
Irène Joliot-Curie (Physics, 1935) Julian Schwinger (Physics, 1965) Pyotr Kapitsa (Physics, 1978) Frank Wilczek (Physics, 2004) Michael Kremer (Economics, 2009) Jack Szostak (Physiology or Medicine, 2009) Robert Lefkowitz (Chemistry, 2012) Victor Ambros (Physiology or Medicine, 2024, obtained Polish citizenship in 2026) John Hopfield (Physics, 2024)
== Philanthropy == In September 2014, Jimmy John's donated $1 million to the Folds of Honor Foundation, a foundation that supports the families of killed or disabled soldiers. During the 2015 school year, Jimmy John's donated more than 100 laptop computers to the Champaign Unit 4 School District. Jimmy John's donated $125,000 to the Champaign Parks Foundation to support the Youth Scholarship Program in November 2016. In June 2017, Jimmy John's donated $100,000 to EAT (RED) SAVE LIVES to offer HIV/AIDS medication in sub-Saharan Africa. In December 2018, Jimmy John's donated $80,000 to pay off all Christmas layaways at Walmart in Champaign, Urbana, and Savoy.
Patients with active internal bleeding Patients with a recent (within 3 months) hemorrhagic stroke Patients with a recent (within 2 months) intracranial/intraspinal surgery/severe head trauma Trauma patients with an increased risk of life-threatening bleeding Patients with an epidural catheter Patients with a known or suspected intracranial neoplasm or mass lesion Patients with known hypersensitivity to drotrecogin or any component
Sources: en.wikipedia.org
35Cl + n → 35S + p It decays by beta-decay with a half-life of 87.51 days. It is used to label the sulfur-containing amino-acids methionine and cysteine. When a sulfur atom replaces an oxygen atom in a phosphate group on a nucleotide a thiophosphate is produced, so 35S can also be used to trace a phosphate group.
Outside the centre stands a bronze statue of Thomas, by John Doubleday. Another monument to Thomas stands in Cwmdonkin Park, one of his favourite childhood haunts, close to his birthplace. The memorial is a small rock in an enclosed garden within the park cut by and inscribed by the late sculptor Ronald Cour with the closing lines from "Fern Hill".
With the presentation of Tiberius as the figure responsible for the retrieval of the standards in the breastplate’s imagery, he would have associated himself in the minds of viewers with the deified emperor and suggested continuity between their reigns, as Augustus himself had done previously with his own deified adoptive father Julius Caesar (though Caesar was not himself an emperor). Under this hypothesis, the dating of the statue can be placed during the first years of Tiberius' reign as emperor (AD 14 — AD 37). However, it is also possible that it was commissioned by Livia herself, Augustus's wife at the time of his death.
The combination of an estrogen and oral or vaginal progesterone has been found to improve cardiovascular health in women in early menopause but not in women in late menopause. Estrogen therapy has a favorable influence on the blood lipid profile, which may translate to improved cardiovascular health. The addition of oral or vaginal progesterone has neutral or beneficial effects on these changes. This is in contrast to various progestins, which are known to antagonize the beneficial effects of estrogens on blood lipids. Progesterone, both alone and in combination with an estrogen, has been found to have beneficial effects on skin and to slow the rate of skin aging in postmenopausal women. In the French E3N-EPIC observational study, the risk of diabetes was significantly lower in women on menopausal hormone therapy, including with the combination of an oral or transdermal estrogen and oral progesterone or a progestin.
==== Regular ==== 22 SAS is under the operational command of the Director Special Forces (DSF), a major-general grade post. Previously ranked as a brigadier, the DSF was promoted from brigadier to major-general in recognition of the significant expansion of the United Kingdom Special Forces (UKSF).
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.